Clinical and economic burden associated with cardiovascular events among patients with hyperlipidemia: A retrospective cohort study

BMC Cardiovascular Disorders

Volumn 16, Issue 1, 2016, Pages

  Fox, Kathleen M ^a,f   Wang, Li ^b   Gandra, Shravanthi R ^c   Quek, Ruben G W ^c   Li, Lu ^b   Baser, Onur ^d,e  

^a Strategic Healthcare Solutions LLC   (United States)

^b STATINMED RESEARCH   (United States)

^c AMGEN INC   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e MEF UNIVERSITY   (Turkey)

^f Strategic Healthcare Solutions   (United States)

Author keywords

Cardiovascular events; Clinical burden; Economic burden; Hyperlipidemia

Indexed keywords

ADULT; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CORONARY ARTERY BYPASS GRAFT; COST OF ILLNESS; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS; ADOLESCENT; AGED; ANGINA, UNSTABLE; CASE CONTROL STUDY; ECONOMICS; FACTUAL DATABASE; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HYPERLIPIDEMIAS; ISCHEMIC ATTACK, TRANSIENT; LENGTH OF STAY; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PROPENSITY SCORE; STATISTICS AND NUMERICAL DATA; STROKE; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANGINA, UNSTABLE; CASE-CONTROL STUDIES; COHORT STUDIES; CORONARY ARTERY BYPASS; DATABASES, FACTUAL; FEMALE; HEALTH CARE COSTS; HEART FAILURE; HOSPITALIZATION; HUMANS; HYPERLIPIDEMIAS; ISCHEMIC ATTACK, TRANSIENT; LENGTH OF STAY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PERCUTANEOUS CORONARY INTERVENTION; PROPENSITY SCORE; RETROSPECTIVE STUDIES; STROKE; UNITED STATES; YOUNG ADULT;

EID: 84954167845     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/s12872-016-0190-x     Document Type: Article

References (39)

1. Bloom DE, Cafiero ET, Jané-Llopis E, Abrahams-Gessel S, Bloom LR, Fathima S, et al., editors. The Global Economic Burden of Non-communicable Diseases. Geneva: World Economic Forum; 2011. http://www.hsph.harvard.edu/program-on-the-global-demography-of-aging/WorkingPapers/2012/PGDA_WP_87.pdf. Accessed 14 July 2015.
2. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics--2015 update: A report from the American Heart Association. Circulation. 2015;131:e29-e322.
3. Soni A. Top 10 most costly condition among men and women 2008: estimates for the U.S. civilian noninstitutionalized adult population, age 18 and older. Medical Expenditure Panel Survey. Statistical Brief 331. http://meps.ahrq.gov/mepsweb/data_files/publications/st331/stat331.shtml. Accessed 14 July 2014.
4. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004;109(21 Suppl 1):II2-10.
5. American Heart Association: Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014;129:e28-e292.
6. Centers for Disease Control and Prevention: High Cholesterol Facts. http://www.cdc.gov/cholesterol/facts.htm. Accessed 14 July 2014.
7. Chapman RH, Liu LZ, Girase PG, Straka RJ. Determining initial and follow-up costs of cardiovascular events in a US managed care population. BMC Cardiovasc Disord. 2011;11:11. doi: 10.1186/1471-2261-11-11.
8. Grover SA, Ho V, Lavoie F, Coupal L, Zowall H, Pilote L. The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins? Arch Intern Med. 2003;163(3):333-9.
9. Trogdon JG, Finkelstein EA, Nwaise IA, Tangka FK, Orenstein D. The economic burden of chronic cardiovascular disease for major insurers. Health Promot Pract. 2007;8(3):234-42.
10. O'Sullivan AK, Rubin J, Nyambose J, Kuznik A, Cohen DJ, Thompson D. Cost estimation of cardiovascular disease events in the US. Pharmacoeconomics. 2011;28(8):693-704.
11. Engelgau MM, Karan A, Mahal A. The economic impact of non-communicable diseases on households in India. Global Health. 2012;8:9. doi: 10.1186/1744-8603-8-9.
12. Leeder S, Raymond S, Greenberg H, Liu H, Esson K. A Race against Time: The Challenge of Cardiovascular Disease in Developing Countries. New York: Columbia University Press; 2004.
13. Eisenstein EL, Shaw LK, Anstrom KJ, Nelson CL, Hakim Z, Hasselblad V, et al. Assessing the clinical and economic burden of coronary artery disease: 1986-1998. Med Care. 2001;39(8):824-35.
14. Etemad LR, McCollam PL. Total first-year costs of acute coronary syndrome in a managed care setting. J Manag Care Pharm. 2005;11(4):300-6.
15. Duh MS, Fulcher NM, White LA, Jayawant SS, Ramamurthy P, Moyneur E, et al. Costs associated with cardiovascular events in patients with hypertension in US managed care settings. J Am Soc Hypertens. 2009;3(6):403-15.
16. Ohsfeldt RL, Gandhi SK, Fox KM, Bullano MF, Davidson M. Medical and cost burden of atherosclerosis among patients treated in routine clinical practice. J Med Econ. 2010;13(3):500-7.
17. Straka RJ, Liu LZ, Girase PS, DeLorenzo A, Chapman RH. Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting. Cardiovasc Diabetol. 2009;8:53. doi: 10.1186/1475-2840-8-53.
18. Stellhorn R, Ciniglio C, Sengupta N. Risk of cardiovascular and major bleeding event rehospitalizations and cost of care among ACS patients in the US. Circ Cardiovas Qual Outcomes. 2012;5:A318.
19. Vlachopoulos CV, Terentes-Printzios DG, Loakeimidis NK, Aznaouridis KA, Stefanadis CI. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction. Circ Cardiovasc Qual Outcomes. 2013;6(1):99-109.
20. Chuang CS, Yang T, Muo CH, Su H, Sung F, Kao C. Hyperlipidemia, statin use and the risk of developing depression: a nationwide retrospective cohort study. General Hospital Psychiatry. 2014;36:497-501.
21. Parsons LS, Ovation Research Group, Seattle, WA. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Paper 214-26. http://www2.sas.com/proceedings/sugi26/p214-26.pdf. Accessed 14 July 2014.
22. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399-424.
23. Normand ST, Landrum MB, Guadagnoli E, Ayanian JZ, Ryan TJ, Cleary PD, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: A matched analysis using propensity scores. J Clin Epidemiol. 2001;54(4):387-98.
24. Asche CV, Kim J, Kulkarni AS, Chakravarti P, Andersson KE. Assessment of association of increased heart rates to cardiovascular events among healthy subjects in the United States: Analysis of a primary care electronic medical records database. Cardiology. Cardiology. 2011;2011:924343. doi: 10.5402/2011/924343.
25. Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM, Hollenberg JP. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol. 2008;61(12):1234-40.
26. Petersen LA, Pietz K, Woodard LD, Byrne M. Comparison of the predictive validity of diagnosis-based risk adjusters for clinical outcomes. Med Care. 2005;43(1):61-7.
27. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45(2):197-203.
28. McGregor JC, Kim PW, Perencevich EN, et al. Utility of the Chronic Disease Score and Charlson Comorbidity Index as comorbidity measures for use in epidemiologic studies of antibiotic-resistant organisms. Am J Epidemiol. 2005;161(5):83-493.
29. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and treatment of high blood cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97.
30. Song X, Quek RG, Gandra SR, Cappell KA, Fowler R, Cong Z. Productivity loss and indirect costs associated with cardiovascular events and related clinical procedures. BMC Health Serv Res. 2015;15:245. doi: 10.1186/s12913-015-0925-x.
31. Weiss AJ, Barrett ML, Steiner CA. Trends and projections in inpatient hospital costs and utilization, 2003-2013. Healthcare Cost and Utilization Project (HCUP) Statistical Brief 175. July 2014. Agency for Healthcare Research and Quality, Rockville, MD. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb175-Hospital-Cost-Utilization-Projections-2013.pdf. Accessed 14 July 2014
32. Caldwell N, Srebotnjak T, Wang T, Hsia R. How much will I get charged for this? Patient charges for top ten diagnoses in the emergency department. PLoS One. 2013;8(2):e55491.
33. Karan A, Engelgau M, Mahal A. The household level economic burden of heart disease in India. Trop Med Int Health. 2014;19(5):581-91.
34. Mahal M, Karan A, Engelgau M. The economic implications for non-communicable disease in India. HNP Discussion Paper, World Bank, January, 2010. http://siteresources.worldbank.org/HEALTHNUTRITIONANDPOPULATION/Resources/281627-1095698140167/EconomicImplicationsofNCDforIndia.pdf. Accessed 14 January 2015
35. Bouillon K, Singh-Manoux A, Jokela M, Shipley MJ, Batty GD, Brunner EJ, et al. Decline in low-density lipoprotein cholesterol concentration: lipid-lowering drugs, diet, or physical activity? Evidence from the Whitehall II study. Heart. 2011;97(11):923-30.
36. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1-45.
37. National Cholesterol Education Program. Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). http://www.nhlbi.nih.gov/files/docs/guidelines/atp3xsum.pdf. Accessed 17 June 2014.
38. Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL-cholesterol reduction with statins: The evidence, etiology and therapeutic challenges. Curr Atheroscler Rep. 2010;14(1):1-10.
39. Dadu RT, Ballantyne CM. Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol. 2014;11(10):563-75.